Neurocrine Biosciences 주식 (NASDAQ: NBIX)

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

Neurocrine Biosciences

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Equities

Large Cap

News

Movers

Trading Ideas

AVTR

ILMN

MRNA

NBIX

PYPL

SWKS

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 스카이웍스 솔루션(NASDAQ:SWKS)의 주식은 회사가 1분기 실적을 발표하고 2분기 가이던스를 예상치 이하로 제시한 후 25.99% 하락했다. 애널리스트들은 주가 전망을 수정했다.

에스티 로더, 모더나 및 페이팔 등 지난주 하락한 10개의 대형주 (2월 3일-7일)

BIRK

CHWY

DOCS

KVYO

TEVA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 테바 파마수티컬스(NYSE:TEVA)의 주식은 회사와 사노피 SA(NASDAQ:SNY)가 궤양성 대장염 및 크론병에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.

테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)

INTC

Citigourp Global Markets 2% Protected Notes Linked To The Djia

SMCI

SNAP

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 슈퍼 마이크로 컴퓨터(NASDAQ:SMCI)의 주식은 8월에 34.89% 하락했다. 이 회사는 10-K 제출을 연기했다.

인텔, 모더나 그리고 달러 제너럴은 8월 최악의 성과를 보인 10개 대형주 중 일부

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

Morgan Stanley analyst Jeffrey Hung assumes Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight rating and lowers Price Target of $150.

Price Target

Initiation

Analyst Ratings

Morgan Stanley Assumes Neurocrine Biosciences at Overweight, Lowers Price Target of $150

Biotech

General

Neurocrine Biosciences Announces Initiation Of Phase 1 Study For NBI-1140675, A Second-Generation VMAT2 Inhibitor, In Healthy Adults For Neurological And Neuropsychiatric Conditions

Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures, including patients with either mild or moderate/severe TD, with improvements observed as early as four weeks at the lowest dose (40 mg). AIMS scores also showed sustained reductions in involuntary movements, regardless of TD severity or underlying psychiatric condition. In the study, safety and tolerability of treatment was consistent with the known profile of INGREZZA, with no new concerns identified.
 &nbsp;

Neurocrine Biosciences Reports Patient-Reported Outcome Data From The KINECT-PRO Study Of INGREZZA; Says 'Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures,'

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

WIIM

Neurocrine Biosciences shares are trading higher after the company authorized a $500 million share repurchase program.

Analysts' ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average reflects an increase of 0.47% from the previous average price target of $168.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1740146453_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Neurocrine Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Neurocrine Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Delving into Neurocrine Biosciences's Background</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin excels beyond industry benchmarks, reaching 16.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 3.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA excels beyond industry benchmarks, reaching 2.84%. This signifies efficient management of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts

Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced that its Board of&nbsp;Directors has authorized a&nbsp;new share&nbsp;repurchase&nbsp;program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.

Buybacks

Neurocrine Biosciences Authorizes $500M Share Repurchase Program; This New Share Repurchase Authorization Is In Addition To The $300M Accelerated Repurchase Program That Was Announced In October 2024 And Completed In Early February 2025

Neurocrine Biosciences shares are trading lower after HC Wainwright & Co. and Guggenheim cut their respective price targets on the stock.

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $165 to $163.

Guggenheim Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $190 to $185.

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $185

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) stock declined 25.99% after the company reported first-quarter earnings and issued second-quarter guidance below estimates. Analysts revised <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) stock plummeted 22.05%  after the company <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares tumbled 19.23% after the company missed its fourth-quarter revenue <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">estimate when reporting financial results</a>. Additionally, HC Wainwright &amp; Co. and B of A Securities lowered <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">their respective price forecasts on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares fell 17.30%, probably after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.&#8217;s nomination to the Senate floor.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) stock was down 16.33% after the company <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">reported fourth-quarter results</a>. Analysts lowered <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) stock decreased 14.23%, probably after President Trump reiterated a pledge to increase oil production.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) shares declined 14.01% after the company reported fourth-quarter results and <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">missed its adjusted EPS estimate</a>.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) stock tumbled 12.72% after the company reported fourth-quarter results and analysts <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>IDEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) shares fell 12.65% following mixed <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts revised <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) shares declined 12.64% after the company reported first-quarter financial results, issued guidance below <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">estimates and cut its FY25 guidance</a>.</li>
</ol>
Photo by Lets Design Studio via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>

Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

<h3>Gainers</h3>
<ul>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares rose 74.0% to $1.34 during Friday's pre-market session. The market value of their outstanding shares is at $43.8 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 73.54% to $2.69. The market value of their outstanding shares is at $4.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 31.55% to $0.21. The market value of their outstanding shares is at $1.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 23.48% to $71.94. The market value of their outstanding shares is at $13.4 billion. The company's, Q3 earnings came out yesterday. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock rose 13.18% to $3.52. The market value of their outstanding shares is at $61.7 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares moved upwards by 12.78% to $3.97. The market value of their outstanding shares is at $188.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares declined by 24.2% to $1.22 during Friday's pre-market session. The market value of their outstanding shares is at $58.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 17.3% to $5.45. The company's market cap stands at $296.5 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares decreased by 16.15% to $126.21. The market value of their outstanding shares is at $12.7 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) stock decreased by 14.9% to $3.03. The company's market cap stands at $168.6 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 13.57% to $9.94. The company's market cap stands at $30.2 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) shares fell 13.02% to $1.27. The market value of their outstanding shares is at $30.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

CYTH

GUTS

NBTX

NVNO

RNXT

STIM

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and lowers the price target from $154 to $148.

RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $148

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and lowers the price target from $157 to $147.

Wedbush Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $147

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $172 to $163.

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.56</a>.
The company reported sales of $627.7 million compared to $515.2 million a year ago, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43544393/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results-and-provides-finan" rel="noreferrer noopener">consensus of $628.99 million</a>.
Ingrezza fourth quarter and fiscal 2024 net product sales were&nbsp;$615 million&nbsp;and&nbsp;$2.3 billion, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43273280/neurocrine-obtains-exclusive-rights-for-depression-drug-takeda-reacquires-japan-rights" rel="noreferrer noopener">Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights</a>
Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by strong underlying patient demand and improvement in gross-to-net dynamics.
Crenessity fourth quarter and fiscal 2024 net product sales were&nbsp;$2 million, reflecting initial pharmacy orders following FDA approval in&nbsp;December 2024
Guidance: Neurocrine Biosciences expects 2025 Ingrezza Net Product Sales of $2.5 billion-$2.6 billion.
William Blair writes that Ingrezza&#8217;s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below investor expectations.
Analyst Myles Minter writes that near-term pressures are weighing on the Ingrezza trajectory. The analyst continues to view Ingrezza as the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.
With Ingrezza still holding 14 years of potential patent protection, William Blair sees a long growth trajectory for the product, but the model addresses near-term competitive pressures ahead of the second-half 2025 salesforce expansion.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">Outperform rating on Neurocrine</a>.
Analyst Reaction:
<ul>
<li>BofA Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences with a Buy and lowers the price target from $184 to $179.</li>
<li>Needham analyst Ami Fadia reiterates the Hold rating.</li>
<li>HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and lowers the price target from $190 to $185.</li>
</ul>
Price Action: NBIX stock is down 191% at $121.98 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps" target="_blank" rel="noreferrer noopener">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection; Stock Jumps</a></li>
</ul>

Analyst Color

Earnings

Guidance

Health Care

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Neurocrine Biosciences shares are trading lower after the company missed its Q4 revenue estimate when reporting financial results. Additionally, HC Wainwright & Co. and B of A Securities lowered their respective price targets on the stock.

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

Press Releases

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

HC Wainwright & Co.

Guggenheim

RBC Capital

Wedbush

이들 10개 대형주는 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 스카이웍스 솔루션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)의 주식은 회사가 1분기 실적을 발표하고 2분기 가이던스를 예상치 이하로 제시한 후 25.99% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">주가 전망을 수정</a>했다.
2. 에스티 로더 컴퍼니즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">2분기 실적을 발표한 후</a> 22.05% 급락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
3. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 회사가 재무 결과를 발표할 때 4분기 매출 <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">예상을 밑돌아</a> 19.23% 하락했다. 또한, HC 웨인라이트와 BofA 증권은는 <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">각각의 주가 전망을 하향 조정</a>했다.
4. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 아마도 상원 재무위원회가 로버트 F. 케네디 주니어의 지명을 상원 본회의로 진전시키기로 투표한 후 17.30% 하락했다.
5. 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">4분기 실적을 발표한 후</a> 16.33% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
6. 벤처 글로벌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>)의 주식은 아마도 트럼프 대통령이 석유 생산을 늘리겠다는 공약을 재확인한 후 14.23% 하락했다.
7. 아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 회사가 4분기 실적을 발표하고 <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">조정 EPS 추정치를 하회한 후</a> 14.01% 하락했다.
8. 페이팔 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>)의 주식은 회사가 4분기 실적을 발표하고 애널리스트들이 <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">주가 전망을 수정한 후</a> 12.72% 하락했다.
9. IDEX 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>)의 주식은 혼재된 <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">4분기 재무 실적</a>에 따라 12.65% 하락했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>했다.
10. PTC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">1분기 재무 실적을 발표하고 가이던스를 예상치 이하로 제시했으며 2025 회계연도 가이던스를 하향 조정한 후</a> 12.64% 하락했다.
사진 출처: Lets Design Studio via Shutterstock
다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%8C%94%EB%9E%80%ED%8B%B0%EC%96%B4-%EC%8A%88%ED%8D%BC-%EB%A7%88%EC%9D%B4%ED%81%AC%EB%A1%9C-%EC%BB%B4%ED%93%A8%ED%84%B0-%EB%B0%8F-%EC%8A%A4%ED%8F%AC%ED%8B%B0%ED%8C%8C%EC%9D%B4-%EB%93%B1-%EC%A7%80/" target="_blank" rel="noopener">팔란티어, 슈퍼 마이크로 컴퓨터 및 스포티파이 등 지난주 상승한 10개 대형주 (2월 3일-2월 7일)</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 테바 파마수티컬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)의 주식은 회사와 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">궤양성 대장염 및 크론병</a>에 대한 두바키투그(Duvakitug)의 2b상 시험에서 1차 평가변수가 충족되었다고 발표한 후 주가는 33.88% 상승했다.
2. 클라비요(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)의 주식은 12.85% 급등했다.
3. 올리브 가든 모회사 다덴 레스토랑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>)의 주식은 회사가 예상보다 좋은 2분기 EPS와 <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">2025 회계연도 매출 전망</a>을 발표한 후 12.54% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 닥시미티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>)의 주식은 10.91% 상승했다. 스티븐스 앤 컴퍼니(Stephens &amp; Co.)가 중립 등급으로 커버리지를 시작하고 <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 $55</a>로 제시했다.
5. 버켄스탁 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>)의 주식은 회사가 예상보다 좋은 4분기 재무 결과와 2025 회계연도 가이던스를 발표한 후 9.70% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
6. 자빌(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>)의 주식은 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">1분기 EPS와 매출</a>을 발표한 후 7.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
7. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 6.88% 상승했다. FDA가 크레네시티(크리네서폰트, crinecerfont) 캡슐과 경구용 용액을 <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">부신피질호르몬 대체 요법 보조 치료제로 승인</a>했다. 이는 4세 이상의 성인 및 소아 환자의 선천성 부신 효소 결핍증(CAH) 치료에 사용된다.
8. 게임스탑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>)의 주식은 지난 주 6.54% 상승했으며, 이는 3분기 실적의 강세가 지속된 결과이다.
9. 닥터 레디스 래버러토리스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>)의 주식은 6.29% 상승했다.
10. 리 오토(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>)의 주식은 지난주 6.13% 상승했다.
사진 제공: Sundry Photography via Shutterstock

이들 10개 대형주는 8월에 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 8월에 34.89% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 연기</a>했다.
2. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 30.95% 하락했다. 이 회사는 예상보다 저조한 2분기 실적을 발표했으며, 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
3. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식은 27.09% 급락했다. 이 회사는 2분기에 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40132594" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 대폭 하향 조정</a>했다.
4. 테무의 모회사 PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 24.81% 하락했다. 이 회사가 분기 실적을 발표하고 CEO가 <a href="https://www.benzinga.com/news/earnings/24/08/40548945/temu-parent-pdd-posts-86-q2-topline-growth-stock-drops-after-ceo-flags-upcoming-challenges?_gl=1%2A2quf99%2A_gcl_au%2ANzQ5NDg4Nzg3LjE3MjI5NDg1NTA.%2A_ga%2AMTUwODg0NTczNy4xNzE1MTcxNjk4%2A_ga_V7ZK73W7N0%2AMTcyNTYyNjczNi4xMzIuMS4xNzI1NjQ0MzU2LjAuMC4w" target="_blank" rel="noreferrer noopener">올해 남은 기간에 대한 도전 과제를 강조</a>했다.
5. 인텔(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)의 주식은 24.13% 하락했다. 이 회사는 저조한 분기 실적과 <a href="https://www.benzinga.com//node/40115276" target="_blank" rel="noreferrer noopener">15% 인력 감축 계획</a>을 발표했다.
6. 텐센트 뮤직 엔터테인먼트 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>)의 주식은 21.44% 하락했다. 이 회사는 2분기 매출이 예상보다 저조하다고 발표하고, <a href="https://www.benzinga.com//node/40373910" target="_blank" rel="noreferrer noopener">애널리스트들이 주가 목표를 하향 조정</a>했다.
6. 골드 필드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>)의 주식은 18.99% 하락했다. 이 회사가 오시스코 마이닝(<a href="https://www.benzinga.com//node/40309407" target="_blank" rel="noreferrer noopener">Osisko Mining)</a>을 15억 7천만 달러 현금으로 인수했다고 밝혔다.
8. 찰스 리버 래보래토리즈 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>)의 주식은 18.57% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40222523" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">분기 실적</a>에서 글로벌 생명공학 고객들의 수요 추세가 약해지고 있다고 경고했습니다.
9. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 <a href="https://www.benzinga.com//node/40514864" target="_blank" rel="noreferrer noopener">17.81% 하락</a>했다.
10. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 17.04% 락했습니다. 이는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">조현병 성인들</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 톱라인 데이터를 제시했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%ea%b7%b8%eb%a6%ac%ea%b3%a0-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4%eb%8a%94-8%ec%9b%94-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">어펌, 쇼피파이 그리고 스타벅스는 8월 최고 성과를 보여준 10개 대형주 중 일부</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 달러 제너럴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>)의 주식은 회사가 2분기 실적과 매출이 예상보다 저조하게 나타났으며 <a href="https://www.benzinga.com//node/40623595" target="_blank" rel="noreferrer noopener">2024년 가이던스를 하향 조정</a>했다고 발표한 후 32.42% 하락했다. 많은 애널리스트들이 <a href="https://www.benzinga.com//node/40656935" target="_blank" rel="noreferrer noopener">주가 목표를 하향 조정</a>했다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40602417" target="_blank" rel="noreferrer noopener">10-K 제출을 지연할 것이라고 발표</a>한 후 20.21% 하락했다.
3. 옥타(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)의 주식은 <a href="https://www.benzinga.com//node/40613044" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 18.69% 하락했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/40625762" target="_blank" rel="noreferrer noopener">회사의 주가 목표를 하향 조정</a>했다.
4. 퓨어 스토리지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40613896" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표한 후 16.88% 하락했다. 애널리스트들이 주가 <a href="https://www.benzinga.com/quote/pstg/analyst-ratings" target="_blank" rel="noreferrer noopener">목표를 하향 조정</a>했다.
5. 뉴로크린 바이오사이언시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>)의 주식은 15.66% 하락했다. 이 회사는 <a href="https://www.benzinga.com//node/40632561" target="_blank" rel="noreferrer noopener">조현병 성인</a>을 대상으로 한 NBI-1117568(NBI-&#8216;568)의 ​​2상 임상 연구에 대한 주요 데이터를 발표했다.
6. 심보틱(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)의 주식은 16.52% 하락했다. <a href="https://www.benzinga.com//node/40575289" target="_blank" rel="noreferrer noopener">짐 크레이머</a>는 &#8220;그 회사는 당신이 가고 싶은 회사가 아니다. 이번 하락 이후에도 너무 높다&#8221;고 말했다.
7. 달러 트리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>)의 주식은 달러 제너럴이 예상보다 저조한 <a href="https://www.benzinga.com//node/40625537" target="_blank" rel="noreferrer noopener">실적과 2024년 가이던스를 발표</a>한 후 12.18% 하락했다.
8. 테무의 모회사 PDD 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식은 CEO가 하반기 도전 과제를 강조한 <a href="https://www.benzinga.com//node/40548945" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a> 발표 후 12.80% 하락했다.
9. 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 7.71% 하락했다.
10. 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주식은 9.76% 하락했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%96%b4%ed%8e%8c-%eb%b0%8f-%eb%aa%bd%ea%b3%a0db%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10%ea%b0%9c-%eb%8c%80%ed%98%95/" target="_blank" rel="noopener">어펌 및 몽고DB는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 25일-8월 31일)</a></li>
</ul>
사진 출처: Shutterstock

Comments

Neurocrine Biosciences

뉴스

에 대한 최신 뉴스 Neurocrine Biosciences (NASDAQ:NBIX) 주식

일요일, 2월 09, 2025

일요일, 12월 22, 2024

일요일, 9월 08, 2024

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌